Michael Best & Friedrich LLP
Isoquinolinone Rho kinase inhibitors
Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.
Aerie Pharmaceuticals, Inc.
A C C A C C C A C C A C A A A C A C
A61K C07D C07D A61K C07D C07D C07D A61K C07D C07D A61K C07D A61P A61K A61P C07D A61K C07D
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Frank Thomas Martin Todd Weimin Erick Richard Roger John Cheng-Kon Michael Robert Sabine K. Anthony S. John David Eugene Richard
Wu Kirrane, Jr. Bosanac Liu Young Snow Shih Turner Schlyer Prokopowicz Ginn Hickey